|
This deal sees Gilead double down on TCEs, following its first bet on the modality through its March buyout of autoimmune-focused Ouro Medicines.
|
 |
|
The duo of funds will support companies across the life sciences landscape – including those in the biopharma, healthcare technology and medtech disciplines.
|
|
|
This deal with insitro sees AstraZeneca double down on its intention to enter the growing MASH market.
|
|
|
Mayo Clinic is prospectively recruiting living ALS patients through an Institutional Review Board-approved protocol.
|
|
|
Acta Pharmaceuticals expects to begin a Phase I clinical trial in October 2026 for its lead asset, GSM-779690T.
|
|
